WHIPPLE DISEASE - ICUNOTES

WHIPPLE DISEASE

AT A GLANCE

Clinical point	Key information
Cause	Rare chronic systemic infection caused by Tropheryma whipplei, a Gram-positive bacterium.
Classic clues	Chronic diarrhoea, weight loss, malabsorption and migratory or intermittent arthralgia/arthritis; systemic features may precede gastrointestinal symptoms by years.
Important extraintestinal sites	Central nervous system (CNS), heart/endocardium, joints, eyes, lymph nodes and lungs.
Diagnosis	Duodenal/small-bowel histology with PAS-positive foamy macrophages, supported by organism-specific PCR and/or immunohistochemistry when available; test involved extraintestinal sites as indicated.
Major pitfall	T. whipplei PCR positivity in stool or saliva alone may reflect carriage and does not establish invasive Whipple disease.
Treatment principle	Prompt antibiotics with adequate CNS penetration, followed by prolonged therapy; regimen and duration depend on disease phenotype.
Do not miss	Neurological signs, culture-negative endocarditis, unexplained systemic illness, or seronegative arthritis with weight loss/malabsorption should raise suspicion.

Table of Contents

1. DEFINITION AND OVERVIEW

Whipple disease is a rare, chronic multisystem infection caused by Tropheryma whipplei. It commonly affects the small intestine but may involve the CNS, heart, joints, eyes, lungs and lymphatic system. Untreated disease can be fatal; prompt diagnosis and prolonged antimicrobial therapy are essential.

Arthralgia or arthritis may precede gastrointestinal symptoms by years, so patients may first present to rheumatology, neurology, cardiology or general medicine.

2. EPIDEMIOLOGY AND PATHOGENESIS

Rare systemic infection; reported more often in middle-aged men, but demographics do not exclude disease.
T. whipplei occurs in the environment; stool/saliva detection may represent asymptomatic carriage.
Why invasive disease develops is unclear; host immune factors likely contribute.
Persistence in macrophages/tissues causes chronic inflammation and malabsorption.

Note: Do not diagnose from demographics or non-sterile-site PCR alone; integrate clinical, histological and organism-specific evidence.

3. CLINICAL FEATURES

System	Manifestations and practical clues
Constitutional	Weight loss, fever, fatigue, weakness, anorexia and wasting.
Gastrointestinal	Chronic diarrhoea, steatorrhoea, abdominal pain, bloating, malabsorption and nutritional deficiencies; gastrointestinal symptoms may appear late.
Musculoskeletal	Intermittent or migratory arthralgia/arthritis, often seronegative; may precede intestinal symptoms by years.
Neurological	Cognitive or behavioural change, confusion, memory impairment, ataxia, seizures, hypothalamic symptoms, supranuclear gaze palsy and movement disorders. Oculomasticatory myorhythmia is a highly characteristic clue.
Cardiac	Culture-negative endocarditis, valvular disease or heart failure; routine blood cultures may not identify the organism.
Lymphatic/other	Lymphadenopathy, hyperpigmentation, pulmonary or pleural manifestations, ocular inflammation and other organ-specific findings.

3.1 Clinical patterns that should trigger suspicion

Chronic diarrhea or weight loss with intermittent, often seronegative arthritis.
Culture-negative endocarditis with constitutional symptoms or arthralgia.
Progressive cognitive, movement or other neurological symptoms, with or without GI symptoms.
Small-bowel villous abnormalities with PAS-positive macrophages.

4. DIAGNOSTIC APPROACH

4.1 Initial assessment

Ask about diarrhoea, weight loss, arthralgia, fever and neurological/cardiac symptoms.
Examine nutrition, joints, heart and nervous system; obtain CBC, renal/liver profile, electrolytes and albumin.
Investigate alternatives in parallel.

4.2 Small-bowel biopsy and histology

Suspected intestinal disease: upper endoscopy with multiple duodenal biopsies.
Histology: villous distortion and PAS-positive, diastase-resistant foamy macrophages.
Exclude acid-fast-positive MAC, which can mimic histology.
If equivocal, discuss tissue-specific T. whipplei PCR/immunohistochemistry.

4.3 Molecular testing and interpretation

Sample/test	Role and limitation
Tissue PCR	Supports diagnosis when histology is equivocal.
CSF PCR	Use for suspected CNS disease; consider in confirmed cases with specialist input.
Involved-site tissue/fluid	PCR/histology may help when an extraintestinal site is affected.
Stool/saliva PCR	Positive result alone may reflect carriage; does not establish invasive disease.
Serology	Not diagnostic alone; antibodies may occur without invasive disease.

4.4 Evaluation for CNS and cardiac involvement

Urgently assess cognitive change, gaze abnormalities, ataxia, seizures or focal signs.
Suspected CNS disease: consider MRI and CSF PCR; normal MRI does not exclude it.
Suspected endocarditis: blood cultures, echocardiography and specialist input; routine cultures may be negative.
Test other involved sites as indicated.

5. DIFFERENTIAL DIAGNOSIS

Condition	Distinguishing considerations
Coeliac disease	Serology and histology in the context of gluten exposure; villous atrophy may overlap, but PAS-positive macrophages are not typical.
Mycobacterium avium complex	May resemble Whipple disease histologically; acid-fast staining and organism-specific testing help distinguish it.
Inflammatory/rheumatological disease	Seronegative arthritis may precede Whipple disease. Reconsider an isolated rheumatological diagnosis when weight loss, diarrhoea, fever or multisystem disease develops.
Other chronic enteropathies/infections	Evaluate according to exposure, immune status, stool testing, medication history and histological pattern.
Other causes of culture-negative endocarditis	Investigate according to endocarditis protocols; T. whipplei is one important possibility in the appropriate clinical context.
Other causes of neurological decline	Use neurological examination, MRI, CSF and targeted testing to assess infectious, inflammatory, neoplastic and degenerative alternatives.

6. MANAGEMENT

6.1 General principles

Correct dehydration, electrolyte disorders, malnutrition, anaemia and deficiencies.
Use T. whipplei-active therapy with CNS penetration; CNS status affects regimen choice.
Prolonged therapy and follow-up are essential; relapse can occur.

6.2 Antimicrobial treatment: evidence-based framing

• A 2025 trial compared ceftriaxone → oral TMP–SMX with oral doxycycline + hydroxychloroquine. Select therapy with specialists based on CNS status, contraindications and interactions.

Regimen described in study	Studied approach	Key caution
IV induction → oral therapy	2025 trial: ceftriaxone 2 g IV daily × 14 days, then TMP–SMX 960 mg orally twice daily × 12 months.	Trial regimen only; check renal function, allergies, interactions and CNS status.
Doxycycline + hydroxychloroquine	2025 trial: doxycycline 100 mg and hydroxychloroquine 200 mg orally, each twice daily × 12 months.	Specialist oversight; assess QT/retinal risk. CNS PCR positivity may alter therapy.
Other induction	Penicillin G or meropenem-based induction is described.	Do not substitute/combine empirically; follow specialist/local protocols.

CNS-PCR-positive patients in the trial’s oral arm also received high-dose TMP–SMX until CSF PCR clearance.

Monitor CBC, renal/liver function, electrolytes, interactions and drug-specific toxicity.
Hydroxychloroquine: assess QT/retinal risk and arrange eye monitoring.
Doxycycline: counsel on photosensitivity/oesophageal irritation; take with water and remain upright.
Individualise therapy for CNS disease, endocarditis, relapse, intolerance or failure.

6.3 Neurological disease and relapse

CNS disease may occur without GI symptoms; promptly assess neurological signs.
Oculomasticatory myorhythmia is characteristic but not always present.
Deterioration: reassess diagnosis, adherence, relapse, CNS coverage, toxicity and alternatives.
Repeat CSF/site tests when indicated and interpret with clinical response.

6.4 Nutritional and supportive care

Monitor weight, hydration and nutrition; replace deficiencies.
Consider dietician input for marked weight loss/malabsorption.

7. COMPLICATIONS

Severe malabsorption, weight loss, protein-calorie malnutrition and micronutrient deficiencies.
CNS disease, including cognitive impairment, movement disorders, seizures and potentially irreversible neurological injury.
Culture-negative endocarditis, valvular damage and heart failure.
Relapse or persistent infection despite initial clinical improvement.
Adverse effects from prolonged antimicrobial therapy.
Delayed diagnosis due to presentation to multiple specialties or misclassification as a primary rheumatological or neurological disorder.

8. PROGNOSIS

With appropriate antibiotics, Whipple disease may be curable; untreated disease can be fatal. Early symptom improvement does not prove eradication, particularly in CNS or cardiac disease. Relapse occurs, and neurological deficits may persist despite control of infection. Long-term follow-up is essential.

9. PRACTICAL CLINICAL PEARLS

Arthralgia may precede gastrointestinal symptoms by years; also consider CNS disease and culture-negative endocarditis.
PAS-positive macrophages are a key clue; distinguish MAC and do not diagnose invasive disease from stool/saliva PCR alone.
Choose therapy with CNS involvement in mind; clinical improvement does not exclude persistence or relapse.

10. WHEN TO SEEK URGENT SPECIALIST INPUT

New confusion, seizures, ataxia, abnormal eye movements or focal neurological deficits.
Suspected culture-negative endocarditis, heart failure or significant valvular disease.
Severe malnutrition, dehydration or inability to maintain oral intake.
Persistent or recurrent symptoms during treatment, suspected relapse, or significant antimicrobial toxicity.
Discordant histology and PCR results, isolated positive non-sterile-site PCR, or suspected disease without intestinal involvement.

11. REFERENCES

Russo TA, Glassman SR. Whipple Disease. In: Loscalzo J, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, eds. Harrison’s Principles of Internal Medicine. 22nd ed. Chapter 181. 2025.
Maiwald M, von Herbay A, Relman DA. Whipple Disease. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran’s Gastrointestinal and Liver Disease. 11th ed. Chapter 109. Elsevier; 2020.
Malik Z. Whipple Disease. Merck Manual Professional Edition. Reviewed March 2025. https://www.merckmanuals.com/professional/gastrointestinal-disorders/malabsorption-syndromes/whipple-disease
Mayo Clinic Staff. Whipple’s disease: Diagnosis and treatment. Updated December 22, 2025. https://www.mayoclinic.org/diseases-conditions/whipples-disease/diagnosis-treatment/drc-20378950
Moos V, Krüger J, Allers K, et al. Oral treatment of Whipple’s disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim-sulfamethoxazole in Germany: a phase 2/3, prospective, open-label, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2025;25(7):788–800. doi:10.1016/S1473-3099(24)00797-7.